700 patients109,892 observations180 daysLIVE

Patient P-02694

Synthetic patientMETA-24 · Day 177 · 25–34 · F · baseline S17Steering view · 3DOpen companion preview
Is the drug working?

Metabolic response 66 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 60%, metabolic response 59 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 127 (sleep −0.8 h); nothing reported yet — the window to act is open.

Still taking it?

55 of 61 scheduled doses in the last 60 days are biologically confirmed (90%); 4 were logged but show no dose signature. Dose signature: resting HR +7 bpm, HRV −8 ms.

last 10 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 184Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the dose at the same time relative to your evening meal
  • 💊No additional supplements this week
Adherence
93% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-02694 is on day 177 of META-24 (MR, baseline S17): response declining, tolerance favorable, GI deteriorating. Over 14 days response moved -5 and GI +4; discontinuation risk is 24%. The state is between basins, heading towards failing, after diverging from the model on day 127.

Biology sets the gain: FUT2 non-secretor; butyrate capacity 55/100, diversity 3.7. Pushing it down: Escherichia coli 13.095% (LPS load) (-42.6), FUT2 non-secretor (-24.3), Bacteroides fragilis elevated (-16.8). Pulling it up: Protein (supports) (+18.7), Butyrate producers intact (+17.1). From the daily log: protein -3.5 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Declining
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
24%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (daily oral dose, morning)
  1. Day 0 META-24 startedBaseline state S17
  2. Day 127 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 127.

Primary contributors, last 14 days
  • GI instability+4
  • Nutritional resilience+4
  • Toxicity+3

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Glucose, CGM daily mean
    CGM
    125 mg/dL
    stable · +3.6 vs previous 14 d
    Active minutes
    Wearable
    68 min
    stable · +1.6 vs previous 14 d
    Sleep duration
    Wearable
    7.5 h
    stable · +0.1 vs previous 14 d
    Energy level
    Daily log
    5.3/10
    stable · +0.2 vs previous 14 d
    Steps
    Wearable
    7,938
    stable · +70 vs previous 14 d
    GI burden
    Companion
    25/100
    worsening · +3.1 vs previous 14 d
    Adherence
    Companion
    92.5 %
    stable · -1.2 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 67 from the failing basin, 22 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    • More protein
      GI -3.5 next day on high-intake days · n 21
    Would not help
    • Nothing clearly counter-productive in the record.
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -3.5supporter · 95%
    • Simple carbohydrates
      +0.9no signal · 25%
    • Insoluble fibre
      -0.9no signal · 26%
    • Dietary fat load
      +0.5no signal · 15%
    • Ultra-processed food
      +0.5no signal · 17%
    • Alcohol
      -0.4no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    44/100
    vs baseline (day 0)
    +3
    3 improved · 3 worsened
    synthetic signature · consistent with this patient's biology
    • 4 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecium
    • 2 keystone species absent
    • Shannon 2.76 (expected ≥ 3)
    • 4 resistance genes
    Pathogens / opportunists4/5
    from 3
    Keystone species2/8
    Diversity1/2
    from 0
    Metabolic modules0/4
    Vitamin synthesis2/7
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling0/1
    from 1
    Central mechanisms0/2
    Virulence factors2/2
    Antibiotic resistance genes4/4
    from 5
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 13.095% AR
    Enterococcus faecium 6.548% AR
    Klebsiella pneumoniae 3.929% AR
    Streptococcus gallolyticus 1.31% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 2.76 · butyrate 725 CPM · SCFA 1137
    2 vitamins below
    Host & mechanisms
    tissue recycling 34/100
    oral translocation 3% AR
    4 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 60
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • MicrobiomeAkkermansia low → thinner mucus layer
    • Autonomic recovery 25
      • WearableResting HR 77 bpm
    • Inflammatory signalling 20
      • MicrobiomeBacteroides fragilis expansion
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    • GLP1R rs6923761 A
      Altered receptor sensitivity
    Microbiome
    Shannon diversity 3.7 · butyrate capacity 55/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    41 ms
    Sleep
    7.8 h
    Steps
    8,320
    Resting HR
    76 bpm
    Daily log: GI score 25, nutritional resilience 62, adherence 93.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Keep fibre steady; no new sources this week
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0242258%S1760
    P-0214855%S0358
    P-0245755%S1364
    P-0262355%S1954
    P-0209253%S04ME-01improved67
    P-0210853%S1957
    P-0267153%S2058
    P-0211852%S1960
    P-0212952%S08BR-03improved59
    P-0254652%S1649
    P-0222951%S1853
    P-0240351%S0961